• Medicine
  • Published in
    Clinical and experimental…
    2007

Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase.

@article{Air2007IntravenousCF,
  title={Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase.},
  author={Paolo Air{\'o} and Elisabetta Danieli and Massimo Rossi and Micol Frassi and Ilaria Cavazzana and Mirko Scarsi and A Grottolo and Franco Franceschini and A Zambruni},
  journal={Clinical and experimental rheumatology},
  year={2007},
  volume={25 2},
  pages={
          293-6
        }
}
OBJECTIVE Cyclophosphamide (CYC) is generally considered the most promising agent available today for systemic sclerosis (SSc)-related interstitial lung disease (ILD). However, the optimal dosage and length of treatment are still undetermined. Our objective was to evaluate the effect of an 18-month long protocol with intravenous (iv) CYC. METHODS In a single-centre, prospective, observational study, 13 patients with SSc and active alveolitis were given 8 iv pulses in a 6-months period (CYC… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 24 CITATIONS

Interstitial lung disease in systemic sclerosis: where do we stand?

Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review

VIEW 1 EXCERPT
CITES BACKGROUND